Why the study?
Timing and intensity regarding resumption of antiplatelet therapy after major bleeding represent a major challenge in clinical practice.
Does the resumption of antiplatelet therapy based on individual risk assessment improve outcomes in high-risk cardiovascular disease patients after major bleeding?
Does the resumption of antiplatelet therapy based on individual risk assessment improve outcomes in high-risk cardiovascular disease patients after major bleeding?
Resuming antiplatelet therapy after major bleeding requires a highly individualized approach balancing thrombotic and bleeding risks through multidisciplinary shared decision-making.
Answers are grounded in this paper and cite their sources.
Supports multidisciplinary decisions after bleeding; leaves open prospective trials to confirm outcome benefits.
Major bleeding is a common threat in patients requiring antiplatelet therapy. Timing and intensity with regard to resumption of antiplatelet therapy represent a major challenge in clinical practice. Knowledge of the patient's bleeding risk, defining transient/treatable and permanent/untreatable risk factors for bleeding, and weighing these against thrombotic risk are key to successful prevention of major adverse events. Shared decision-making involving various disciplines is essential to determine the optimal strategy. The present article addresses clinically relevant questions focusing on the most life-threatening or frequently occurring bleeding events, such as intracranial hemorrhage and gastrointestinal bleeding, and discusses the evidence for antiplatelet therapy resumption using individual risk assessment in high-risk cardiovascular disease patients.
No takes yet. Share an insight, caveat, or question.
Geisler et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: